KBC Group’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$49K Hold
6,557
﹤0.01% 1663
2025
Q4
$77K Hold
6,557
﹤0.01% 1454
2025
Q3
$51K Hold
6,557
﹤0.01% 1643
2025
Q2
$48K Hold
6,557
﹤0.01% 1620
2025
Q1
$62K Hold
6,557
﹤0.01% 1723
2024
Q4
$108K Buy
6,557
+2,027
+45% +$31.5K ﹤0.01% 1503
2024
Q3
$67K Buy
4,530
+1,127
+33% +$17.6K ﹤0.01% 1556
2024
Q2
$47K Hold
3,403
﹤0.01% 1653
2024
Q1
$53K Hold
3,403
﹤0.01% 1526
2023
Q4
$55K Sell
3,403
-394
-10% -$6.45K ﹤0.01% 1460
2023
Q3
$47K Sell
3,797
-6,289
-62% -$93.5K ﹤0.01% 1496
2023
Q2
$162K Hold
10,086
﹤0.01% 1004
2023
Q1
$176K Sell
10,086
-767
-7% -$10.9K ﹤0.01% 1017
2022
Q4
$100K Hold
10,853
﹤0.01% 1198
2022
Q3
$93K Hold
10,853
﹤0.01% 1219
2022
Q2
$88K Buy
+10,853
New +$104K ﹤0.01% 1277
2021
Q3
Sell
-2,090
Closed -$94K 1320
2021
Q2
$94K Hold
2,090
﹤0.01% 1236
2021
Q1
$100K Hold
2,090
﹤0.01% 1243
2020
Q4
$619K Buy
+2,090
New +$94.4K ﹤0.01% 1188
2019
Q4
Sell
-29,097
Closed -$556K 1531
2019
Q3
$556K Hold
29,097
﹤0.01% 1048
2019
Q2
$638K Hold
29,097
﹤0.01% 987
2019
Q1
$595K Buy
+29,097
New +$506K ﹤0.01% 1032

Other funds holding NEO

KBC Group's NEO Position: Q1 2026 in Review

KBC Group held its NeoGenomics (NEO) position steady in Q1 2026 at 6,557 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #1663.

KBC Group first reported a position in NEO in Q1 2019 and has held it in 22 quarters since. The position peaked at $638K in Q2 2019. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.

  • KBC Group held 6,557 shares of NeoGenomics worth $49K as of Q1 2026.
  • KBC Group left its NeoGenomics share count unchanged in Q1 2026.
  • NeoGenomics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1663 holding.
  • KBC Group first reported a position in NeoGenomics in Q1 2019 and has held it in 22 quarters since.
  • KBC Group's NeoGenomics position peaked at $638K in Q2 2019.
  • 253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.